Drug Profile
Ebselen - Sound Pharmaceuticals
Alternative Names: DR-3305; Ebselene; Ebseleno; Ebselenum; Harmokisane; PZ-51; SPI-1005; SPI-3005Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Nattermann
- Developer Daiichi Sankyo Company; Medical University of South Carolina; Nattermann; Sound Pharmaceuticals; University of Oxford
- Class Anti-ischaemics; Antiasthmatics; Antibacterials; Antiulcers; Antivirals; Azoles; Benzene derivatives; Ketones; Mood stabilisers; Neuroprotectants; Nonsteroidal anti-inflammatories; Organoselenium compounds; Small molecules; Vascular disorder therapies; Vestibular disorder therapies
- Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Glutathione peroxidase stimulants; Leukotriene B4 receptor antagonists; Prostaglandin receptor antagonists; Viral papain like protease inhibitors; Viral protein inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Meniere's disease
- Phase II Bipolar disorders; COVID 2019 infections; Hearing loss; Noise-induced hearing loss; Sensorineural hearing loss; Tinnitus
- Phase I Depressive disorders
- Discontinued Asthma; Atherosclerosis; Cerebral infarction; Myocardial ischaemia; Peptic ulcer; Rheumatic disorders
Most Recent Events
- 08 Mar 2024 Ebselen is still in phase III trial for Meniere's disease in USA (PO) (NCT04677972)
- 30 Jan 2024 Efficacy and pharmacodynamics data from a phase-II clinical trials in Hearing loss released by Sound Pharma
- 03 May 2023 Sound Pharmaceuticals completes enrolment in the phase III STOPMD-3 trial for Meniere's-disease in USA (PO) (NCT04677972)